biomarker News
-
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients in order to evaluate the use of their novel biomarker, Seravue®, for the purposes of detecting Hepatocellular Carcinoma in its early and later stages. ...
-
Commitment to Access, Quality and Growth through Innovation
Dynacare Launches JOINTstat® Testing in Canada Augurex is pleased to announce the launch of JOINTstat (14-3-3?) testing services through Dynacare, one of Canada’s largest and most established health solution companies with a dedicated mission to support healthy lives with commitment and care. This arrangement will make JOINTstat testing accessible to more patients and physicians ...
-
Showcase
VisionQuest Abstract on Diabetic Peripheral Neuropathy Accepted by ADA
We’re looking forward to presenting “Detecting Diabetic Peripheral Neuropathy Utilizing Thermoregulation of the Plantar Foot” at the upcoming 82nd Scientific Sessions of the American Diabetes Association. Our research aims to detect thermal (infrared) biomarkers of diabetic peripheral neuropathy on the feet of diabetic subjects who have not been diagnosed with DPN. By analyzing ...
-
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients in order to evaluate the use of their novel biomarker, Seravue®, for the purposes of detecting Hepatocellular Carcinoma in its early and later stages. ...
-
Independent Clinical Study Shows Seravue® Has High Sensitivity And Specificity For The Detection Of Liver Cancer In Nafld And Related Cirrhotic Patients
A recent study has been published by investigators at the University of Turin in the peer-reviewed journal Current Oncology. This study focused on the performance of Seravue and the LC-SPIK biomarker in detecting hepatocellular carcinoma (HCC) in a pool of nonalcoholic fatty liver disease (NAFLD) related cirrhosis patients. Here, LC-SPIK had an AUC of 0.841 and significantly outperformed AFP, the ...
-
Assessing CDM measures in grey matter micro structure in AD Patients for Takeda Pharmaceuticals
Oxford Brain Diagnostics has started a project for Takeda Pharmaceuticals. The project is testing Cortical Disarray Measurement (CDM®) technology as a neurodegeneration biomarker with a view to using it in future clinical trials. Dr Steven Chance, CEO, said ‘we are very excited to be engaged with Takeda on this project using our CDM method on diffusion MRI scans. Alzheimer’s ...
-
Biomark to Present New Cancer Screening Data using the Ldtd-Ms/Ms Technique at The Annual Asms Conference on Mass Spectrometry
BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its poster abstract has been accepted for presentation at the upcoming 70th Annual Conference of the American Society for Mass Spectrometry (ASMS) taking place on June 5 – 9, 2022 ...
-
Biomark Announces Closing of $1,5 Million Financing Round to Accelerate Commercialization of Its Liquid Biopsy Technology
BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed a financing round to accelerate the commercialization of its liquid biopsy technology. The financing round included a non-brokered private ...
-
Showcase
Primary Results of Onawa (Solti-1802) Trial: A Window Of Opportunity Trial Of Onapristone In Postmenopausal Women With Progesterone Receptor-Positive/Her2-Negative Early Breast Cancer
PGR is an estrogen-responsive gene and progesterone receptor (PR) expression, evaluated by immunohistochemistry (IHC), is used as a clinical biomarker of estrogen signaling and estrogen receptor (ER) functionality.1 Despite the well-studied role of PGR as mitogen and independent ER activator, anti-progestins for the treatment of BC have been poorly tested. While limited success for ...
-
Amadix selected by the European Commission as one of the companies granted with the program EIC Accelerator
EIC Accelerator is the biggest funding round supported by the European Commission, with a total budget of 637 million euros and more than 90 million euros to be distributed between the 11 Spanish start-ups selected, including Amadix. To be part of the EIC Accelerator is a big boost for the company and the commercialization of Amadix’ firs product, PREVECOL® (previously known as ...
By Amadix
-
The US Patent Office Grants BIOMARK Additional Patent for its LIQUID BIOPSY Technology
Vancouver, British Columbia – (September 20, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US Patent Office (USPTO) has granted BioMark patent number US 11,447,168 that covers a novel approach to diagnosing ...
-
Autism Biomarkers Could Save Billions in Healthcare Costs According to Recent Study
The use of accurate biomarkers for detecting autism spectrum disorder (ASD) could result in saving billions of dollars in healthcare costs, according to a paper recently published in the journal Autism Research. Titled "Evidence–based Use of Scalable Biomarkers to Increase Diagnostic Efficiency and Decrease the Lifetime Costs of Autism," the paper showed that if more children with ASD are ...
-
You`re invited to our webinar `How to Screen Binding Kinetics in 3 Easy Steps with the New EzPlex System`.
During this webinar you will learn how the new features of the fully-automated EzPlex system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ideal for biomarker discovery, biotherapeutics research, antibody and aptamer production, protein analysis, and cellular ...
-
You`re invited to our webinar `How to Screen Binding Kinetics in 3 Easy Steps with the New EzPlex System`.
During this webinar you will learn how the new features of the fully-automated EzPlex system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ideal for biomarker discovery, biotherapeutics research, antibody and aptamer production, protein analysis, and cellular ...
-
GI Innovation Signs MoU with CellKey for Biomarker Joint Research to Develop Next-generation Innovative Immuno-oncology
Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next-generation immuno-oncology, personalized cancer treatment effects… increasing reliability and efficiency of treatment GI Innovation, an innovative new drug development company, announced on ...
-
BioMark Receives Funding, Support, Research and Development Project for Cancer Treatment Monitoring
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat ...
-
“Detecting Diabetic Peripheral Neuropathy Utilizing Thermoregulation Biomarkers of the Plantar Foot” Poster Presentation
VisionQuest founder and CEO Peter Soliz (PhD) presented the poster “Detecting diabetic peripheral neuropathy utilizing thermoregulation biomarkers of the plantar foot” at the American Diabetes Association’s 82nd Scientific Sessions last Sunday in New Orleans. “I was so glad to be able to meet with colleagues and make new connections in person after not traveling for over ...
-
ISPRM 2022 is now over - Lisbon PT
ISPRM 2022 is now over | International Society of Physical and Rehabilitation Medicine | Lisbon PT After 4 nice days and some smart presentations, ISPRM 2022 now ends with great memories. New device presentation: IVS4 for Lower Limbs as a complementary approach to balance exercise, strengthening and robotic rehabilitation for gait recovery Lecture: Comparison of EEG biomarkers in Mirror ...
-
GI Innovation singed MoU with CellKey for joint biomarker research for development of next generation innovative immuno-oncology.
Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next generation immuno-oncology, personalized cancer treatment effects… increasing Reliability and efficiency of treatment GI Innovation, a new innovative drug development company, announced on February ...
-
Join us on April 8th, 2015 to learn more about the capabilities of XelPleX for multiplex label-free interaction analysis.
Join us on April 8th, 2015 to learn more about the capabilities of XelPleX for multiplex label-free interaction analysis. During this webinar you will learn how the new features of the fully-automated XelPleX system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you